LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,089
تعداد مقالات9,995
تعداد مشاهده مقاله26,518,195
تعداد دریافت فایل اصل مقاله7,299,598
Maleksabet, Amir, Zarei Jaliani, Hossein, Asgari, Amir, Ramezani, Amin, Erfani, Nasrollah. (1400). Specific Targeting of Recombinant Human Pancreatic Ribonuclease 1 using Gonadotropin-Releasing Hormone Targeting Peptide toward Gonadotropin-Releasing Hormone Receptor-Positive Cancer Cells. سامانه مدیریت نشریات علمی, 46(4), 281-290. doi: 10.30476/ijms.2020.83234.1219
Amir Maleksabet; Hossein Zarei Jaliani; Amir Asgari; Amin Ramezani; Nasrollah Erfani. "Specific Targeting of Recombinant Human Pancreatic Ribonuclease 1 using Gonadotropin-Releasing Hormone Targeting Peptide toward Gonadotropin-Releasing Hormone Receptor-Positive Cancer Cells". سامانه مدیریت نشریات علمی, 46, 4, 1400, 281-290. doi: 10.30476/ijms.2020.83234.1219
Maleksabet, Amir, Zarei Jaliani, Hossein, Asgari, Amir, Ramezani, Amin, Erfani, Nasrollah. (1400). 'Specific Targeting of Recombinant Human Pancreatic Ribonuclease 1 using Gonadotropin-Releasing Hormone Targeting Peptide toward Gonadotropin-Releasing Hormone Receptor-Positive Cancer Cells', سامانه مدیریت نشریات علمی, 46(4), pp. 281-290. doi: 10.30476/ijms.2020.83234.1219
Maleksabet, Amir, Zarei Jaliani, Hossein, Asgari, Amir, Ramezani, Amin, Erfani, Nasrollah. Specific Targeting of Recombinant Human Pancreatic Ribonuclease 1 using Gonadotropin-Releasing Hormone Targeting Peptide toward Gonadotropin-Releasing Hormone Receptor-Positive Cancer Cells. سامانه مدیریت نشریات علمی, 1400; 46(4): 281-290. doi: 10.30476/ijms.2020.83234.1219

Specific Targeting of Recombinant Human Pancreatic Ribonuclease 1 using Gonadotropin-Releasing Hormone Targeting Peptide toward Gonadotropin-Releasing Hormone Receptor-Positive Cancer Cells

Iranian Journal of Medical Sciences
مقاله 6، دوره 46، شماره 4، مهر 2021، صفحه 281-290    اصل مقاله (2.19 M)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2020.83234.1219
نویسندگان
Amir Maleksabet1، 2؛ Hossein Zarei Jaliani3؛ Amir Asgari4، 5؛ Amin Ramezani1، 2؛ Nasrollah Erfani* 2، 6
1Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
2Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3Department of Medical Biotechnology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
4School of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
5Cardiovascular Research Centre, University of Alberta, Edmonton, AB, Canada
6Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Targeted drug delivery is a novel method to specifically deliver anticancer therapeutics to tumor sites. Gonadotropin-releasing hormone (GnRH) is a decapeptide, and its target binding property has attracted attention as a means of targeted drug delivery. Human pancreatic ribonuclease 1 (hpRNase1) has been shown to exert anticancer properties, when fused to a targeting moiety. The goal of the present study was to add a GnRH targeting peptide to the N-terminus of hpRNase1 to specifically target GnRH receptor (GnRH-R) expressing cells.
Methods: This in vitro study was conducted at Shiraz Institute for Cancer Research (Shiraz, Iran) in 2019. The coding sequence of GnRH and hpRNase1 were fused, and the chimeric protein together with non-fused hpRNase1 were produced in E. coli (BL21). The recombinant proteins were purified, and their biological activity was evaluated using MTT and apoptosis assays. Non-parametric Kruskal–Wallis tests with Dunn’s post hoc tests were performed to determine the significant differences between the study groups.
Results: GnRH-hpRNase1 chimeric protein specifically inhibited the proliferation of PC-3 (P=0.021), LNCaP (P=0.034), and AD-Gn (P=0.041) cells, while the growth of negative cells (AD-293) was not significantly affected (P=0.081). GnRH-hpRNase1 decreased the IC50 values more than non-fused hpRNase1, by approximately 26.5-fold (P=0.036) for PC-3 cells, and exerted its growth inhibitory effects through apoptosis induction.
Conclusion: Fusion of GnRH to hpRNase1 structure produced an enzyme, which could specifically target tumor cells. This approach can be used to eliminate tumors that harbor GnRH-R.
کلیدواژه‌ها
Drug delivery systems؛ Ribonucleases؛ Pancreatic؛ Gonadotropin-releasing hormone
سایر فایل های مرتبط با مقاله
مراجع
  1. Mousavizadeh A, Jabbari A, Akrami M, Bardania H. Cell targeting peptides as smart ligands for targeting of therapeutic or diagnostic agents: a systematic review. Colloids Surf B Biointerfaces. 2017;158:507-17. doi: 10.1016/j.colsurfb.2017.07.012. PubMed PMID: 28738290.
  2. Zhao N, Qin Y, Liu H, Cheng Z. Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy. Anticancer Agents Med Chem. 2018;18:74-86. doi: 10.2174/1871520617666170419143459. PubMed PMID: 28425855.
  3. Kheirandish MH, Jaliani HZ, Rahmani B, Nikukar H. Specific targeting of a pore-forming toxin (listeriolysin O) to LHRH-positive cancer cells using LHRH targeting peptide. Toxicon. 2019;164:82-6. doi: 10.1016/j.toxicon.2019.04.005. PubMed PMID: 30991063.
  4. Le Joncour V, Laakkonen P. Seek & Destroy, use of targeting peptides for cancer detection and drug delivery. Bioorg Med Chem. 2018;26:2797-806. doi: 10.1016/j.bmc.2017.08.052. PubMed PMID: 28893601.
  5. Lozza C, Navarro-Teulon I, Pelegrin A, Pouget JP, Vives E. Peptides in receptor-mediated radiotherapy: from design to the clinical application in cancers. Front Oncol. 2013;3:247. doi: 10.3389/fonc.2013.00247. PubMed PMID: 24093086; PubMed Central PMCID: PMCPMC3782707.
  6. Limonta P, Montagnani Marelli M, Mai S, Motta M, Martini L, Moretti RM. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev. 2012;33:784-811. doi: 10.1210/er.2012-1014. PubMed PMID: 22778172.
  7. Grundker C, Emons G. The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis. Front Endocrinol (Lausanne). 2017;8:187. doi: 10.3389/fendo.2017.00187. PubMed PMID: 28824547; PubMed Central PMCID: PMCPMC5543040.
  8. Boonthum C, Namdee K, Boonrungsiman S, Chatdarong K, Saengkrit N, Sajomsang W, et al. Chitosan-based DNA delivery vector targeted to gonadotropin-releasing hormone (GnRH) receptor. Carbohydr Polym. 2017;157:311-20. doi: 10.1016/j.carbpol.2016.09.015. PubMed PMID: 27987933.
  9. Goodwin D, Varamini P, Simerska P, D’Occhio MJ, Toth I. Design, synthesis and evaluation of a gonadotropin releasing hormone-based subunit vaccine in rams (Ovis aries). Vaccine. 2015;33:1453-8. doi: 10.1016/j.vaccine.2015.01.076. PubMed PMID: 25678242.
  10. Qi L, Nett TM, Allen MC, Sha X, Harrison GS, Frederick BA, et al. Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor. Cancer Res. 2004;64:2090-5. doi: 10.1158/0008-5472.can-3192-2. PubMed PMID: 15026348.
  11. Azar Y, Lorberboum-Galski H. GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins. Apoptosis. 2000;5:531-42. doi: 10.1023/a:1009689529756. PubMed PMID: 11303912.
  12. Jordaan S, Akinrinmade OA, Nachreiner T, Cremer C, Naran K, Chetty S, et al. Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells. Biomedicines. 2018;6. doi: 10.3390/biomedicines6010028. PubMed PMID: 29510557; PubMed Central PMCID: PMCPMC5874685.
  13. Kiesgen S, Arndt MAE, Korber C, Arnold U, Weber T, Halama N, et al. An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo. Cancer Lett. 2015;357:364-73. doi: 10.1016/j.canlet.2014.11.054. PubMed PMID: 25434798.
  14. Porta C, Paglino C, Mutti L. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. Biologics. 2008;2:601-9. doi: 10.2147/btt.s2383. PubMed PMID: 19707441; PubMed Central PMCID: PMCPMC2727885.
  15. Squiquera L, Taxman DJ, Brendle SA, Torres R, Sulley J, Hodge T, et al. Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase I study. Antivir Ther. 2017;22:247-55. doi: 10.3851/IMP3133. PubMed PMID: 28121292.
  16. Rutkoski TJ, Raines RT. Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity. Curr Pharm Biotechnol. 2008;9:185-9. doi: 10.2174/138920108784567344. PubMed PMID: 18673284; PubMed Central PMCID: PMCPMC2818677.
  17. Rutkoski TJ, Kink JA, Strong LE, Raines RT. Human ribonuclease with a pendant poly(ethylene glycol) inhibits tumor growth in mice. Transl Oncol. 2013;6:392-7. doi: 10.1593/tlo.13253. PubMed PMID: 23908681; PubMed Central PMCID: PMCPMC3730013.
  18. Asgari A, Sharifzadeh S, Ghaderi A, Hosseini A, Ramezani A. In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells. Mol Biol Rep. 2019;46:6205-13. doi: 10.1007/s11033-019-05059-0. PubMed PMID: 31493284.
  19. Lomax JE, Bianchetti CM, Chang A, Phillips GN, Jr., Fox BG, Raines RT. Functional evolution of ribonuclease inhibitor: insights from birds and reptiles. J Mol Biol. 2014;426:3041-56. doi: 10.1016/j.jmb.2014.06.007. PubMed PMID: 24941155; PubMed Central PMCID: PMCPMC4219644.
  20. Castro J, Ribó M, Benito A, Vilanova M. Approaches to Endow Ribonucleases with Antitumor Activity: Lessons Learned from the Native Cytotoxic Ribonucleases. Anti-cancer Drugs: Nature, Synthesis and Cell. 2016:135.
  21. Riccio G, D’Avino C, Raines RT, De Lorenzo C. A novel fully human antitumor immunoRNase resistant to the RNase inhibitor. Protein Eng Des Sel. 2013;26:243-8. doi: 10.1093/protein/gzs101. PubMed PMID: 23232187; PubMed Central PMCID: PMCPMC3572756.
  22. Leland PA, Staniszewski KE, Kim BM, Raines RT. Endowing human pancreatic ribonuclease with toxicity for cancer cells. J Biol Chem. 2001;276:43095-102. doi: 10.1074/jbc.M106636200. PubMed PMID: 11555655.
  23. Qin Y, Chen H, Zhang Q, Wang X, Yuan W, Kuai R, et al. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm. 2011;420:304-12. doi: 10.1016/j.ijpharm.2011.09.008. PubMed PMID: 21945185.
  24. Rizzuti M, Nizzardo M, Zanetta C, Ramirez A, Corti S. Therapeutic applications of the cell-penetrating HIV-1 Tat peptide. Drug Discov Today. 2015;20:76-85. doi: 10.1016/j.drudis.2014.09.017. PubMed PMID: 25277319.
  25. Farokhinejad F, Behbahani AB, Rafiei Dehbidi GR, Takhshid MA. Expression and purification of TAT-NDRG2 recombinant protein and evaluation of its anti-proliferative effect on LNCaP cell line. Protein Expr Purif. 2017;138:25-33. doi: 10.1016/j.pep.2017.07.004. PubMed PMID: 28711733.
  26. Kristensen M, Birch D, Morck Nielsen H. Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos. Int J Mol Sci. 2016;17. doi: 10.3390/ijms17020185. PubMed PMID: 26840305; PubMed Central PMCID: PMCPMC4783919.
  27. Haigis MC, Raines RT. Secretory ribonucleases are internalized by a dynamin-independent endocytic pathway. J Cell Sci. 2003;116:313-24. doi: 10.1242/jcs.00214. PubMed PMID: 12482917; PubMed Central PMCID: PMCPMC2812863.
  28. De Lorenzo C, Nigro A, Piccoli R, D’Alessio G. A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. FEBS Lett. 2002;516:208-12. doi: 10.1016/s0014-5793(02)02527-9. PubMed PMID: 11959134.
  29. Psarras K, Ueda M, Tanabe M, Kitajima M, Aiso S, Komatsu S, et al. Targeting activated lymphocytes with an entirely human immunotoxin analogue: human pancreatic RNase1-human IL-2 fusion. Cytokine. 2000;12:786-90. doi: 10.1006/cyto.1999.0619. PubMed PMID: 10843765.
  30. Hoshimoto S, Ueda M, Jinno H, Kitajima M, Futami J, Seno M. Mechanisms of the growth-inhibitory effect of the RNase-EGF fused protein against EGFR-overexpressing cells. Anticancer Res. 2006;26:857-63. PubMed PMID: 16619480.
  31. Zewe M, Rybak SM, Dubel S, Coy JF, Welschof M, Newton DL, et al. Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnology. 1997;3:127-36. doi: 10.1016/s1380-2933(97)00070-5. PubMed PMID: 9237097.
  32. Futami J, Seno M, Ueda M, Tada H, Yamada H. Inhibition of cell growth by a fused protein of human ribonuclease 1 and human basic fibroblast growth factor. Protein Eng. 1999;12:1013-9. doi: 10.1093/protein/12.11.1013. PubMed PMID: 10585508.
  33. Menzel C, Schirrmann T, Konthur Z, Jostock T, Dubel S. Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood. 2008;111:3830-7. doi: 10.1182/blood-2007-04-082768. PubMed PMID: 18230757.
  34. D’Avino C, Palmieri D, Braddom A, Zanesi N, James C, Cole S, et al. A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy. Oncotarget. 2016;7:87016-30. doi: 10.18632/oncotarget.13522. PubMed PMID: 27894092; PubMed Central PMCID: PMCPMC5349967.
آمار
تعداد مشاهده مقاله: 2,922
تعداد دریافت فایل اصل مقاله: 1,768


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب